Bacteria. Clinical isolates and samples, control strains, and recipients in conjugation experiments are listed in table I [7] . Microorganisms were identified as described [6] . Plasmid pJMM 1 was obtained from S. enterica subsp. enterica serotype Othmarschen RYC36536. For susceptibility testing of the strains, MICs were determined by agar dilution according to standard guidelines [8] .
fJ-lactamase analysis. Analytical isoelectric focusing was done with cel1-free lysates obtained by ultrasonication as described [9] .
Conjugation experiments. Transfer of resistance from ceftazidime-resistant strains to susceptible recipients was done with 8 S. enterica subsp. enterica serotype Othmarschen strains (I from each patient), as well as with Escherichia coli RYC5Hand Enterobacter cloacae RYC39737 (ceftazidime-resistant strains recovered during the same outbreak). In the experiment, a total of 10 7 cfu/mL donor cells were mixed with an equal number of recipient cells (E. coli K-12 BM21), and mating was done on brain-heart infusion (Difco, Detroit) agar plates for 18 h. Transconjugants were selected on Luria-Bertani agar plates containing 40 j.lg/mL nalidixic acid and 15 j.lg/mL ceftazidime. Nalidixic acid-resistant mutants of the originally ceftazidime-susceptible S. enterica subsp. enterica serotype Othmarschen RYCl1982 and RYC22459 strains (11982 Nx' and 22459 Nx') were selected on Luria-Bertani agar plates containing 40 j.Lg/mL nalidixic acid and used as recipients in conjugation experiments. Transconjugants were selected on Luria-Bertani agar plates containing 40 j.lg/mL nalidixic acid and 15 j.Lg/mL ceftazidime.
Plasmid analysis. Isolation and restriction of plasmid DNA from transconjugants of the 8 selected Salmonella strains and from E. coli RYC5H and E. cloacae RYC39737 isolates were done as described by Sambrook et a1. [10] .
Genomic DNA extraction. Chromosomal DNA from Salmonella control strains and clinical isolates for PCR experiments was extracted as described [11] , except that treatment with proteinase K was not done.
Oligonucleotides and peR amplification. Oligonucleotide primers were obtained from Operon Technologies (Alameda, CA Rise andfall ofthe epidemic Salmonella isolates. Detection of the epidemic strain was greatly facilitated by the unusual lactose-positive character of the involved Salmonella isolates. In all cases, these strains were identified as S. enterica subsp. enterica serotype Othmarschen (6,7:g,m,t) (hereafter referred checked against the chosen Salmonella strains, the control strain Salmonella arizonae ATee 12323, and 6 S. enterica subsp. entertea serotype Othrnarschen strains not related to the outbreak (table  1) . Among several primers that proved to be adequate for the discrimination of strains, we selected for analysis purposes those primers that rendered the better-defined DNA banding patterns. Amplification reactions were done following the protocol indicated by the manufacturer, except for a previous DNA denaturing step of 10 min at 94°C and a final extension reaction of 5 min at n°e.
Taq DNA polymerase was purchased from Promega (Madison, WI). Samples were amplified in a PTC-IOO thermocycler (MJ Research, Watertown, MA) as follows: 45 cycles of 1 min at 94°C, 1 min at 36°C, and 2 min at 72°C. Amplified DNA products were detected by electrophoresis at 80 V in 1.4% agarose gels stained with ethidium bromide. Because of the potential variation of AP-PCR, experiments were done in triplicate on discontinuous days. to as S. enterica). Four and 2 months before the outbreak of ceftazidime-resistant S. enterica isolates in the PCICU, 2 of these lactose-positive S. enterica strains, fully susceptible to antibiotics, were isolated from blood cultures of 2 newborns admitted in the Cardiology Department. One of these patients (patient 1; figure 1 ) was subsequently transferred to the PCICU. Here, 3 weeks later, a biochemically and serologically identical S. enterica strain resistant to ampicillin, cefazolin, and gentamicin was isolated from feces of the same patient. Retrospectively analyzed, this strain may have been the first strain harboring TEM-27, but cefotaxime and ceftazidime were not included at this time in the routine susceptibility testing of stool isolates. One month later, the first confirmed ceftazidime-resistant (TEM-27 -mediated), lactose-positive S. enterica strain was recovered from blood cultures of a newborn attending the PCICU. Extensive bacteriologic studies on 8 patients attending the PCICU concurrently yielded a total of 23 phenotypically identical S. enterica isolates (10 from stool samples, 9 from respiratory secretions, 2 from surgical wounds, and 2 from intravascular catheters). Of the 8 patients involved, 6 were considered clinically infected (3 of them died) and 2 were considered colonized (l died). The strain E. cloacae RYC39737, with an almost identical resistance pattern, was detected from an intravascular catheter culture where S. enterica was also obtained. All infected or colonized patients were isolated to prevent further cross-infection in the PCICU. Another enteric organism presenting the same antibiotic resistance phenotype, E. coli RYC5H, was obtained from a stool culture from a patient not infected with S. enterica. This patient was also isolated. The infected and colonized patients had the following previous treatment schedules: cefazolin (2 patients), cefazolin and gentamicin or tobramycin (2 patients), cefazolin and amoxicillin-clavulanate (2 patients), ampicillin and gentamicin (l patient), and ceftazidime and gentamicin (1 patient). At the time of the isolation of the resistant Salmonella strain, 4 patients (3 infected, 1 colonized) were being treated with ceftazidime in combination with gentamicin or tobramycin (1 case each) or with vancomycin (2 cases). The other 4 children were receiving cefazolin (2 cases), cefazolin plus tobramycin (l case), and amoxicillin-clavulanate (1 case). As previously described [6] , the epidemic was controlled in 6 weeks, after ceftazidime and cefotaxime restriction policy (imipenem was used as an alternative), stringent isolation of patients and carriers, emphasis on handwashing procedures, and extensive disinfection of the PCICU. During the period of the epidemic (JuneJuly), 98 patients were admitted to the PCICU (stay range, 1-46 days), and only 8 were colonized or infected by Salmonella, meaning that the routine measures ofprevention of crossinfection were effective to a certain extent.
Unexpectedly, a new S. enterica TEM-27 -harboring isolate (RYC2790), with identical serotype, was found 18 months after the epidemic in the bronchial secretion of a 12-year-old cystic fibrosis patient, previously treated with aztreonam and who attended the Cystic Fibrosis Unit of the hospital but without any documented relationship with the Table 2 shows the MICs of ,B-Iactams obtained for prototype S. enterica strain RYC36536 (all strains displayed an identical antibiotic susceptibility pattern), E. coli RYC5H, and E. cloacae RYC39737. The Salmonella strain showed a high resistance level to ceftazidime (512 f-lg/mL) and aztreo- nam (64 f-lg/mL) but much less to cefotaxime (2 j1g/mL) and ceftizoxime (1 f-lg/mL). E. coli RYC5H expressed lower-level resistance, with a cefotaxime MIC of only 0.2 f-lg/mL. E. cloacae RYC39737 had a ceftazidime MIC of 128 j1g/mL and cefotaxime MIC of 1 j1g/mL, again inferior to the levels expressed by S. enterica. All strains were susceptible to amikacin but resistant to the other aminoglycosides tested and remained susceptible to tetracycline, chloramphenicol, trimethoprim, nalidixic acid, and ftuoroquinolones. Plasmid analysis. No plasmid content was found in both antibiotic-susceptible lactose-positive S. enterica strains RYC11982 and RYC22459. As previously reported, the prototype S. enterica RYC36536 harbored a 59-kb conjugative plasmid that encoded TEM-27 [6] . A plasmid of identical size was found in E. coli RYC5H and in E. cloacae RYC39737 strains. E. coli RYC5H also had a plasmid of 2.2 kb (not shown). In all cases, the 59-kb plasmid was transferred to E. coli K-12 BM21 and to nalidixic acid -resistant S. enterica variant strains RYCl1982 Nx T and RYC22459 Nx' at a frequency of (related to number of the donor strains after 1 h of mating). 
Discussion
The emergence in a pediatric unit of an infrequent lactosepositive biotype of S. enterica subsp , enterica, the sudden acquisition of ceftazidimc resistance, and the simultaneous appearance of nearly identical resistance pattern in other enteric genera defined an interesting scenario to be investigated by the application of the tools of molecular epid emiology. 1\ combination of plasmid profile analysis with AP-PCR was used in this study . The dispe rsion of a single Salmon ella enterica subsp. enterica serotype Othmarschen clone in the PCTCD was documented. At the same time, the results obtained demonstrate the epidemic nature of plasmid pJMMI harbored by the ceftazidime-resistant strains, which proved capable of disseminating among different Enterobacteriaceae.
The occasion for in vivo tran sfer seem s to be particularly frequent among members of the Enterobacteriaceae, as they frequently share the same habitat in the intestine [12, 13] . In the epidemic studied here, it could be suggested that the lactosepositive S. enterica strain acquired the plasmid pJMM I from another Enterobacteriaceae family member, perhaps from E. coli RYC5H or E. cloacae RYC39737, if they were previously 1 2 3 4 5 6
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{3-lactamase isoelectric fo cusing. All studied ccftazidimcresistant Salmonella isolates produced the same {3-lactamase TEM-27, focusing at pI 5.9 [6] .
E. coli RYC5H expressed two {3-lactamases, one of pl 5.4 compatible with TEM-I and the other of pI 5.9 compatible with TEM-27. E. cloacae RYC39737 produced two {3-lactamases: a presumptive chromosomal {3-lactamase (pl 8.8) and again a pl 5.9 enzyme consi stent with TEM-27. Resistance profiles in the last 2 strains support the presence of the new extended-spectrum {3-lactamase.
AP-PCR. PCR amplification of chromosomal DNA from all clinical S. enterica strains isolated during the outbreak, susceptible or resistant to ceftazidime, yielded a unique banding pattern, with both the OPA-3 (5'-AGTCAGCCAC-3') and OPA-18 (5'-AGGTGACCGT-3') primers (figure 4). Results were highly reproducible, although occasional slight variations in the intensity of amplified bands were observed. These variations do not influence the evaluation of results . To demonstrate that the method was reliable for differentiating within the serotype , PCR amplification was done with 6 control S. enterica subsp. enterica serotype Othmarschen strains unrelated to the outbreak (figure 5). Two of these strains (CNSS 1717/95 and CNSSI0737/95) shared the same banding pattern with both OPA-3 ( figure 5 ) and OPA-18 (not shown), and all others had independent banding patterns. None ofthese patterns was found [5, [14] [15] [16] [17] [18] . Some of the key factors determining this situation may be found in the very peculiar ecologic landscape of pediatric intensive care units, even in hospitals in developed areas: relatively easy oral-fecal bacterial transmission and particularly susceptible hosts. In our case , the high frequency of isolates found in respiratory samples supports the importance of the fecal-oral route; on the other hand, a relative immunosuppression and malnutrition frequently follows intensive surgery. The influence of previous antibiotic therapy in our patients could also have been invoked as a factor contributing to the selection of the resistant strains. Cefazolin and gentamicin were the most frequently used antibiotics in the patients during the period preceding the epidemic. These antibiotics may have been directly involved in the selective process of the resistant Salmonella strain; on the other hand, their contribution could be the unspecific decrease of the colonization resistance of the hosts, thereby lowering the infectious dose and enhancing the transmissibility of the epidemic strain. More specifically, at the time of the Salmonella isolation, 2 patients were being treated with ceftazidime and aminoglycoside and another 2 with ceftazidime plus vancomycin. Ceftazidime-in particular in association with an aminoglycoside-should be considered as a very selective agent for TEM-27 -harboring Salmonella isolates. In summary, the overall use of antibiotics in the PCICU may have been a facilitating factor for the epidemic spread, and the use of ceftazidime-aminoglycoside combinations a factor determining the specific selection of the resistant strain. The results obtained in this work stress the importance of the early detection and close epidemiologic surveillance of bacterial strains with high potential rate of transmission, in the prevention of the dissemination of new resistance mechanisms.
